research Treatment of Post-COVID-19 Telogen Effluvium
Topical Minoxidil is effective for hair loss after COVID-19.
Search
forLearn
0 / 0 results — no results
Research
5 / 540 results 
research Clinical Profile of Female Patients With Chronic Telogen Effluvium and Its Association With Serum Ferritin Level
Low iron levels may be linked to hair loss in women.
research Clinical Profile of Female Patients With Chronic Telogen Effluvium and Its Association With Serum Ferritin Level
Low iron levels may be linked to hair loss in women with chronic telogen effluvium.
research Pathogenic Mechanisms And Mechanism-Directed Therapies For Androgenetic Alopecia: Current Understanding And Future Directions
Targeting multiple pathways may improve treatments for androgenetic alopecia.
research Frequency, Severity, and Related Factors of Androgenetic Alopecia in Dermatology Outpatient Clinic: Hospital-Based Cross-Sectional Study in Turkey
AGA more common in men, increases with age, linked to family history, hypertension, dyslipidemia, and smoking.
Community Join
4 / 4 results
community Should i be worried dut 6 months
by
Metro_V
in General
122 upvotes
2 months ago The user has been using finasteride and minoxidil, then switched to dutasteride and minoxidil for six months without significant results, noticing thinning after increasing creatine dosage. They plan to consult a dermatologist to explore potential causes beyond androgenetic alopecia.
community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied
by
nkrata
in Research
830 upvotes
1 year ago Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
community Kintor stealing pictures from a hair transplant clinic to promote their failed product (KX826, Pyrilutamide)
Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.